A dendritic cell vaccine administered before and after autologous stem cell transplant (ASCT) was safe and immunogenic and was associated with durable clinical responses in patients with high-risk multiple myeloma. The results were published on September 22, 2023 in Clinical Cancer Research, with senior author Frederick L. Locke, MD, Chair of the Blood and Marrow Transplant and Cellular Immunotherapy Department at Moffitt Cancer Center. “Multiple myeloma is a chronic and incurable cancer,” said Locke. “Dendritic cell vaccines have the potential to harness the patients’ own immune system to get them into remission and potentially keep the cancer from coming back.” The CCR article is titled “Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control After Autologous Transplant in Patients with Myeloma.”